cediranib + cisplatin + gemcitabine

This is a combination drug regimen consisting of three agents used primarily in chemotherapy for advanced biliary tract cancer. - Cediranib is an oral small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors VEGFR1, VEGFR2, and VEGFR3, with additional activity against platelet-derived growth factor receptors (PDGFR) and c-KIT. It acts by inhibiting angiogenesis which tumors require for growth. - Cisplatin is a platinum-based chemotherapeutic agent that causes DNA crosslinking leading to apoptosis of rapidly dividing cells. - Gemcitabine is a nucleoside analog that inhibits DNA synthesis by incorporation into DNA strands causing chain termination. The combination aims to enhance antitumor efficacy by combining cytotoxic chemotherapy (cisplatin and gemcitabine) with anti-angiogenic targeted therapy (cediranib). However, clinical trials have shown that adding cediranib to the standard cisplatin and gemcitabine regimen did not improve progression-free survival in patients with advanced biliary tract cancer. The combination remains investigational regarding the benefit of cediranib addition[1][2][6].